Icagen is now part of Pfizer’s Worldwide Research and Development organization, and will be integrated into Neusentis, Pfizer’s Research Unit which includes Pain, Sensory Disorders and Regenerative Medicine.
Pfizer senior vice president Ruth McKerna said Icagen is known for its expertise in pain research.
"Their understanding of ion channel mechanisms will enhance our ability to develop novel drugs for the treatment of pain and related disorders," McKerna added.